Maya Horst

Dr. Maya Horst


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2019 in Frontiers in Pediatrics
Verified
Journal Article
Open access
PDF file
MHMaya Horst
Maya Horst
DEDaniel Eberli
Daniel Eberli
RGRita Gobet
Rita Gobet
SSSouzan Salemi
Souzan Salemi
Several congenital disorders can cause end stage bladder disease and possibly renal damage in children. The current gold standard therapy is enterocystoplasty, a bladder augmentation using an intestinal segment. However, the use of bowel tissue is associated with numerous complications such as metabolic disturbance, stone formation, urine leakage, chronic infections, and malignancy. Urinary diversions using engineered bladder tissue would obviate the need for bowel for bladder reconstruction. Despite impressive progress in the field of bladder tissue engineering over the past decades, the successful transfer of the approach into clinical routine still represents a major challenge. In this review, we discuss major achievements and challenges in bladder tissue regeneration with a focus on different strategies to overcome the obstacles and to meet the need for living functional tissue replacements with a good growth potential and a long life span matching the pediatric population.

15 November 2016 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
PDF file
MHMaya Horst
Maya Horst
LMLuca Mazzone
Luca Mazzone
TSThomas Schraner
Thomas Schraner
CBChristine Bodmer
Christine Bodmer
UMUeli Möhrlen
Ueli Möhrlen
RGRita Gobet
Rita Gobet

18 May 2020 in Journal of Biomedical Materials Research Part B: Applied Biomaterials
Verified
Journal Article
Closed access
PDF file
JSJakub Smolar
Jakub Smolar
DNDaniele De Nardo
Daniele De Nardo
ERErnst Reichmann
Ernst Reichmann
RGRita Gobet
Rita Gobet
DEDaniel Eberli
Daniel Eberli
MHMaya Horst
Maya Horst

1 September 2020 in Tissue Engineering Part A
Verified
Journal Article
Closed access
JSJakub Smolar
Jakub Smolar
MHMaya Horst
Maya Horst
SSSouzan Salemi
Souzan Salemi
DEDaniel Eberli
Daniel Eberli
All organs of human body are a conglomerate of various cells types with multi-directional interplay between the different cells and the surrounding microenvironment, leading to a stable tissue formation, homeostasis and function. In order to develop a functional smooth muscle tissue, we need to simulate and create a multicellular microenvironment. The multi-lineage adipose-derived stem cells (ADSC), which can be easily harvested in large numbers, may provide an alternative cell source for the replacement of smooth muscle cells (SMC) in cell-based detrusor bioengineering therapeutic approaches. The aim of this study was to investigate whether pre-differentiated smooth muscle-like ADSC (pADSC) can support SMC to generate stable smooth muscle tissue trough remodeling of ECM and factor secretion. Rat SMC and pADSC were mono- and co-cultured in the cell ratios 1:1, 1:2, 1:3 and 1:5 (SMC-pADSC) and grown for up to two weeks in vitro. The expression of the SMC-specific markers alpha smooth muscle actin (αSMA), calponin, myosin heavy chain 11 (MyH11) and smoothelin was assessed and cell proliferation and contractility analyzed. Proteomic analysis of the secretome (cell-cell contact were compared to a 1:1 non-contact co-culture) and the cell pellets was performed, with the focus on ECM deposition and remodeling, integrin expression and growth factor secretion. SMC and pADSC were strongly positive for all smooth muscle markers. After one and two weeks of culture, the 1:1 cell ratio developed a significantly higher number of smooth muscle organoids and improved contractility. These organoids were highly structured, consisting of an SMC core surrounded by a pADSC layer. The deposition of various EMC proteins, such as collagens 1a1, 1a2, 2a1, 3a1, 5a2, 6a2, 12a1 and fibrillin 1 was significantly increased. A decreased MMP3, MMP9 and MMP13 secretion, as well as an increased TIMP1 and TIMP2 secretion were found in the contact co-culture compared to the monoculture controls. SMC-pADSC 1:1 co-cultures exhibits an improved cell proliferation, contractility and organoid formation compared to all other ratios and monoculture, while retaining a stable phenotype that is comparable to the SMC monoculture. These effects are mediated by increased ECM deposition and tight ECM remodeling by the secreted MMP and TIMP.

Verified
Journal Article
Open access
PDF file
DPDafni Planta
Dafni Planta
TGTim Gerwinn
Tim Gerwinn
SSSouzan Salemi
Souzan Salemi
MHMaya Horst
Maya Horst
Spinal dysraphism, most commonly myelomeningocele, is the typical cause of a neurogenic lower urinary tract dysfunction (NLUTD) in childhood. The structural changes in the bladder wall in spinal dysraphism already occur in the fetal period and affect all bladder wall compartments. The progressive decrease in smooth muscle and the gradual increase in fibrosis in the detrusor, the impairment of the barrier function of the urothelium, and the global decrease in nerve density, lead to severe functional impairment characterized by reduced compliance and increased elastic modulus. Children present a particular challenge, as their diseases and capabilities evolve with age. An increased understanding of the signaling pathways involved in lower urinary tract development and function could also fill an important knowledge gap at the interface between basic science and clinical implications, leading to new opportunities for prenatal screening, diagnosis, and therapy. In this review, we aim to summarize the evidence on structural, functional, and molecular changes in the NLUTD bladder in children with spinal dysraphism and discuss possible strategies for improved management and for the development of new therapeutic approaches for affected children.

Verified
Journal Article
Open access
PDF file
SSSouzan Salemi
Souzan Salemi
LSLarissa J. Schori
Larissa J. Schori
TGTim Gerwinn
Tim Gerwinn
MHMaya Horst
Maya Horst
DEDaniel Eberli
Daniel Eberli
Cell therapies and tissue engineering approaches using smooth muscle cells (SMCs) may provide treatment alternatives for end-stage lower urinary tract dysfunction (ESLUTD). Myostatin, a negative regulator of muscle mass, is a promising target to improve muscle function through tissue engineering. The ultimate goal of our project was to investigate the expression of myostatin and its potential impact in SMCs derived from healthy pediatric bladders and pediatric ESLUTD patients. Human bladder tissue samples were evaluated histologically, and SMCs were isolated and characterized. The proliferation of SMCs was assessed by WST-1 assay. The expression pattern of myostatin, its pathway and the contractile phenotype of the cells were investigated at gene and protein levels by real-time PCR, flow cytometry, immunofluorescence, WES and gel contraction assay. Our results show that myostatin is expressed in human bladder smooth muscle tissue and in isolated SMCs at gene and protein levels. A higher expression of myostatin was detected in ESLUTD-derived compared to control SMCs. Histological assessment of bladder tissue confirmed structural changes and decreased muscle-to-collagen ratios in ESLUTD bladders. A decrease in cell proliferation and in the expression of key contractile genes and proteins, α-SMA, calponin, smoothelin and MyH11, as well as a lower degree of in vitro contractility was observed in ESLUTD-derived compared to control SMCs. A reduction in the myostatin-related proteins Smad 2 and follistatin, and an upregulation in the proteins p-Smad 2 and Smad 7 were observed in ESLUTD SMC samples. This is the first demonstration of myostatin expression in bladder tissue and cells. The increased expression of myostatin and the changes in the Smad pathways were observed in ESLUTD patients. Therefore, myostatin inhibitors could be considered for the enhancement of SMCs for tissue engineering applications and as a therapeutic option for patients with ESLUTD and other smooth muscle disorders.